Feature

The potential problem(s) with a once-a-year COVID vaccine


 

Just a ‘first step’ toward annual shot

The currently updated COVID vaccine may be the first step toward an annual vaccine, but it’s only the first step, Dr. Schaffner said. “We haven’t committed to further steps yet because we’re watching this virus.”

Syra Madad, DHSc, MSc, an infectious disease epidemiologist at Harvard University’s Belfer Center for Science and International Affairs, Cambridge, Mass., and the New York City hospital system, told this news organization that arguments on both sides make sense.

Having a single message once a year can help eliminate the considerable confusion involving people on individual timelines with different levels of immunity and separate campaigns for COVID and flu shots coming at different times of the year.

“Communication around vaccines is very muddled and that shows in our overall vaccination rates, particularly booster rates,” she says. “The overall strategy is hopeful and makes sense if we’re going to progress that way based on data.”

However, she said that the data are just not there yet to show it’s time for an annual vaccine. First, scientists will need to see how long protection lasts with the Omicron-specific vaccine and how well and how long it protects against severe disease and death as well as infection.

COVID is less predictable than influenza and the influenza vaccine has been around for decades, Dr. Madad noted. With influenza, the patterns are more easily anticipated with their “ladder-like pattern,” she said. “COVID-19 is not like that.”

What is hopeful, she said, “is that we’ve been in the Omicron dynasty since November of 2021. I’m hopeful that we’ll stick with that particular variant.”

Dr. Topol, Dr. Schaffner, and Dr. Madad declared no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

FDA authorizes updated COVID boosters to target newest variants
Journal of Clinical Outcomes Management
CDC gives final approval to Omicron COVID-19 vaccine boosters
Journal of Clinical Outcomes Management
Asymptomatic infections drive many epidemics, including monkeypox, polio, and COVID
Journal of Clinical Outcomes Management
Unvaccinated 10 times more likely to be hospitalized for Omicron
Journal of Clinical Outcomes Management
New study supports safety of COVID-19 boosters during pregnancy
Journal of Clinical Outcomes Management
CDC says 44% of people hospitalized with COVID had third dose or booster
Journal of Clinical Outcomes Management
Low testosterone may raise risk of COVID hospitalization
Journal of Clinical Outcomes Management
Vitamin D supplementation shows no COVID-19 prevention
Journal of Clinical Outcomes Management
Why some infectious disease docs are ‘encouraged’ by new bivalent COVID vaccines
Journal of Clinical Outcomes Management
Full-dose antithrombotic aids selected COVID-19 ICU patients
Journal of Clinical Outcomes Management